嵌合抗原受体技术治疗神经母细胞瘤的研究进展

Research advances of chimeric antigen receptor technology in the treatment of neuroblastoma

神经母细胞瘤(neuroblastoma,NB)是儿童中枢神经系统外常见的实体肿瘤,对于高危的NB患儿,即使综合多种治疗手段,预后仍较差。嵌合抗原受体技术在血液系统肿瘤的治疗中已广泛运用,且疗效已得到证实。近些年,嵌合抗原受体技术对于NB等实体瘤的治疗得到了持续的发展,为NB的治疗带来了新的理念和思路。

Neuroblastoma is the most common solid extracranial malignancy in infants.The prognosis of children with high-risk neuroblastoma remains poor even after a variety of treatments.Chimeric antigen receptor technology has been widely applied for hematological tumors(including neuroblastoma)and clinical efficacy has been definite.In recent years,chimeric antigen receptor technology has made great progress in the treatment of solid tumors such as neuroblastoma.